Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 18/20 | 0.74 |
| ▸ | JAK2 | O60674 | 2/20 | 0.60 |
| ▸ | BRD4 | O60885 | 2/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.60 |
| ▸ | FYN | P06241 | 1/20 | 0.60 |
| ▸ | FES | P07332 | 1/20 | 0.60 |
| ▸ | RET | P07949 | 1/20 | 0.60 |
| ▸ | ROS1 | P08922 | 1/20 | 0.60 |
| ▸ | CDK4 | P11802 | 1/20 | 0.60 |
| ▸ | SRC | P12931 | 1/20 | 0.60 |
| ▸ | JAK1 | P23458 | 1/20 | 0.60 |
| ▸ | TYK2 | P29597 | 1/20 | 0.60 |
| ▸ | JAK3 | P52333 | 1/20 | 0.60 |
| ▸ | EPHB1 | P54762 | 1/20 | 0.60 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.60 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1674005 | 1.00 | PTK2 (0.74) | PTK2JAK2BRD4LCKFYN | |
| SCHEMBL30540747 | 0.89 | PTK2 (0.75) | PTK2JAK2BRD4LCKFYN | |
| SCHEMBL29523727 | 0.88 | PTK2 (0.73) | PTK2JAK2BRD4LCKFYN | |
| SCHEMBL1674397 | 0.88 | PTK2 (0.73) | PTK2JAK2BRD4LCKFYN | |
| SCHEMBL1674050 | 0.85 | PTK2 (1.00) | PTK2JAK2BRD4LCKFYN | |
| SCHEMBL18334677 | 0.84 | PTK2 (0.74) | PTK2JAK2BRD4LCKFYN | |
| SCHEMBL29523722 | 0.84 | PTK2 (0.74) | PTK2JAK2BRD4LCKFYN | |
| SCHEMBL1674187 | 0.84 | PTK2 (0.74) | PTK2JAK2BRD4LCKFYN | |
| SCHEMBL17461676 | 0.83 | PTK2 (0.78) | PTK2JAK2BRD4LCKFYN | |
| SCHEMBL1673993 | 0.83 | PTK2 (0.78) | PTK2JAK2BRD4LCKFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735462-A1 | COMPOUNDS AND USES THEREFOR | GLYCOSYNNOVATIONS PTY LTD (AU) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735463-A1 | COMPOUNDS AND USES THEREFOR | GLYCOSYNNOVATIONS PTY LTD (AU) | 2026-05-06 | — | — | EP | disclosed |
| EP-4565577-A1 | INHIBITORS AND USES THEREFOR | Macquarie University (AU) | 2025-06-11 | — | — | EP | disclosed |
| EP-4556010-A2 | JAK INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF A VIRAL DISEASE CAUSED BY A CORONAVIRIDAE | Emory University (US) | 2025-05-21 | — | — | EP | disclosed |
| WO-2025000061-A1 | COMPOUNDS AND USES THEREFOR | Glycosynnovations Pty Ltd (AU) | 2025-01-02 | — | — | WO | disclosed |
| WO-2025000059-A1 | COMPOUNDS AND USES THEREFOR | Glycosynnovations Pty Ltd (AU) | 2025-01-02 | — | — | WO | disclosed |
| EP-4319764-A2 | THIONUCLEOSIDES AS ANTIVIRAL AGENTS | Emory University (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-4319762-A2 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | Emory University (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-4319763-A2 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | Emory University (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2024026540-A1 | INHIBITORS AND USES THEREFOR | MACQUARIE UNIVERSITY (AU) | 2024-02-08 | — | — | WO | disclosed |
| WO-2022217155-A2 | THIONUCLEOSIDES AS ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022217154-A2 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | EMORY UNIVERSITY (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022217153-A2 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022170396-A1 | AGENTS AND METHODS FOR THERAPY AND PROPHYLAXIS | ViraLok Therapeutics Pty Ltd (AU) | 2022-08-18 | — | — | WO | disclosed |
| EP-3980400-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | Emory University (US) | 2022-04-13 | — | — | EP | disclosed |